Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.46 |
| ▸ | GSK3A | P49840 | 5/20 | 0.46 |
| ▸ | GSK3B | P49841 | 5/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.46 |
| ▸ | CLK2 | P49760 | 3/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21687421 | 0.91 | CLK4 (0.44) | CLK4GSK3AGSK3BKDRSTK17A | |
| SCHEMBL21687782 | 0.91 | CLK4 (0.44) | CLK4GSK3AGSK3BKDRSTK17A | |
| SCHEMBL15483262 | 0.84 | CCNC (0.52) | CLK4GSK3AGSK3BKDRSTK17A | |
| SCHEMBL2328345 | 0.79 | FERMT2 (0.51) | CLK4GSK3AGSK3BKDRSTK17A | |
| SCHEMBL23928759 | 0.79 | KDM4E (0.54) | CLK4GSK3AGSK3BKDRSTK17A | |
| SCHEMBL30274560 | 0.79 | KDM4E (0.54) | CLK4GSK3AGSK3BKDRSTK17A | |
| SCHEMBL8541628 | 0.78 | FERMT2 (0.57) | CLK4GSK3AGSK3BKDRSTK17A | |
| SCHEMBL18290322 | 0.76 | FERMT2 (0.64) | FERMT2HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL18290329 | 0.74 | FERMT2 (0.62) | FERMT2HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL5240032 | 0.74 | CLK4 (0.55) | CLK4GSK3AGSK3BKDRSTK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242531-B2 | Compositions and methods for the treatment of hypercholesterolemia | CITY OF HOPE (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242531-B2 | Compositions and methods for the treatment of hypercholesterolemia | CITY OF HOPE (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200040343-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-06 | — | — | US | disclosed |
| US-20200040343-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040343-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | LDLR, APOB, PCSK9 | CLK4 1835/4885GSK3A 2065/4885GSK3B 2303/4885 |
| US-11242531-B2 | Compositions and methods for the treatment of hypercholesterolemia | LDLR, APOB, PCSK9 | CLK4 1835/4885GSK3A 2065/4885GSK3B 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.